Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2020-07-16 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport kv 2 2020' (Interim Report Q2 2020) for Orexo. It contains comprehensive financial statements, including income statements, balance sheet data, segment reporting, management commentary on business trends, and outlook for the fiscal year. It is clearly a quarterly financial report, not an announcement of a report or a simple press release. Q2 2020
2020-07-16 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report Q2 2020' and contains comprehensive financial statements, including income statements, balance sheet data, segment reporting, and management commentary on financial performance. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2020
2020-07-16 English
Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces the US launch of digital therapies and provides updated financial guidance (OPEX guidance for FY 2020). It contains key financial highlights, strategic updates, and details about an upcoming teleconference/presentation. This structure—a formal announcement of results, guidance changes, and strategic moves, often released before a full report or alongside an earnings release—is characteristic of an Earnings Release (ER) or a general press release covering financial performance updates. Since it provides updated financial guidance (OPEX guidance) and discusses sales potential, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results and key highlights. It is not a full 10-K, an Interim Report (IR), or just a presentation (IP). It is an announcement of financial performance and outlook.
2020-07-02 English
Orexo lanserar deprexis® och vorvida® i USA och ger uppdaterad finansiell guidning
Earnings Release Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces the launch of digital therapies (deprexis® and vorvida® in the USA) and provides updated financial guidance for 2020 (increasing OPEX). It details strategic business decisions, market potential, and upcoming conference calls. This content structure—announcing significant business updates, financial outlook changes, and product launches via a press release format—is characteristic of an Earnings Release (ER) or a general business update. Since it provides updated financial guidance (OPEX increase) and discusses commercialization plans following product launches, it functions as an initial announcement of financial performance context and strategic changes, fitting the definition of an Earnings Release (ER) better than a comprehensive Interim Report (IR) or a simple Report Publication Announcement (RPA). The final sentence confirms it is information Orexo AB is required to disclose under EU market abuse regulation, typical for material announcements like earnings or major strategic shifts. FY 2020
2020-07-02 Swedish
Number of shares and votes in Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release dated May 29, 2020, announcing an update to the total number of shares and votes in Orexo AB following a cancellation resolved at the Annual General Meeting (AGM) on April 16, 2020. This announcement details a change in the capital structure (specifically the number of shares outstanding) due to a corporate action (share cancellation). This fits best under 'Share Issue/Capital Change' (SHA) as it directly reports a change in the total number of shares. While it mentions the AGM, the core content is the resulting share count change, not AGM materials (AGM-R) or voting results (DVA). It is not a full financial report (10-K, IR) or an earnings release (ER).
2020-05-29 English
Antal aktier och röster i Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release ("Pressmeddelande") dated May 29, 2020, announcing a change in the total number of shares and votes following the cancellation of C-shares decided at the Annual General Meeting (AGM) on April 16, 2020. The core subject is the resulting capital structure (34,710,639 ordinary shares and votes). This directly relates to changes in the company's capital structure or share count, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it details the final count after a capital action (share cancellation). It is not an AGM-R (which would be the meeting materials), nor is it a DVA (which would be the official voting results, although related to the AGM decision). Since it explicitly states the resulting share count after a capital adjustment, SHA is the most precise fit over the general RNS.
2020-05-29 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.